References Library
A complete bibliography of peer-reviewed publications, clinical trial registrations, and regulatory documents cited throughout this knowledge base. All references follow academic citation standards.
70 references indexed
2026
-
Bajaj HS, Welch M, Shah P, et al.
Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial
The Lancet . 407 : 2402-2413 (2026)
phase-3 transcend-t2d-1 type-2-diabetes -
Bellido V, le Roux CW, Ekinci EI, et al.
Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial
The Lancet (published online September 29, 2026) . 408 : 1455-1472 (2026)
phase-3 triumph-2 type-2-diabetes -
Bloomberg News
Novo to cut Ozempic and Wegovy prices amid intense competition (February 24, 2026; Wegovy list price $1,349 a month, Ozempic more than $1,000, both to $675 from January 1, 2027)
Bloomberg News, via The Spokesman-Review (2026)
pricing semaglutide -
Buzzi RM, Huber LC
Emerging risks of health optimisation: refractory nausea associated with peptide injections reported to contain retatrutide
BMJ Case Reports . 19(10) : e276106 (2026)
gray-market case-report safety -
U.S. Court of Appeals for the Seventh Circuit
Eli Lilly and Company v. Kennedy, No. 26-1301: order of September 24, 2026 directing supplemental memoranda on appellate jurisdiction (argued September 24, 2026; memoranda filed October 8, 2026)
Federal court docket (2026)
regulatory litigation -
Gilbert D
Two deaths were reported to the FDA. Is the bootleg weight-loss drug 'Reta' to blame?
CBS News (updated October 13, 2026) (2026)
gray-market safety news -
Yamaguchi A, Geller L
We bought and tested what was sold as an experimental weight loss drug. The lab results were "pretty terrifying."
CBS News (October 21, 2026) (2026)
gray-market counterfeit news -
Centers for Medicare & Medicaid Services
CMS Launches Medicare GLP-1 Bridge, Expanding Access to GLP-1 Medications (July 1, 2026); Medicare GLP-1 Bridge: Information for Providers
CMS Newsroom (2026)
medicare pricing insurance -
Eli Lilly and Company
Pre-approval Expanded Access of Retatrutide (LY3437943), NCT07629401 (single-patient expanded access; status: Available)
ClinicalTrials.gov record (first posted June 5, 2026; updated August 6, 2026) (2026)
expanded-access compassionate-use ClinicalTrials.gov -
U.S. Food and Drug Administration
FDA Approves First New Molecular Entity Under National Priority Voucher Program (April 1, 2026)
FDA News Release (2026)
regulatory orforglipron -
U.S. Food and Drug Administration
Warning Letter to Peptide Partners LLC (MARCS-CMS 735063): unapproved new drugs including 'GLP-3 Reta (Retatrutide)' marketed as research use only
FDA Warning Letter (August 24, 2026) (2026)
FDA warning-letter gray-market enforcement -
U.S. Food and Drug Administration, Center for Drug Evaluation and Research
Letter to Eli Lilly and Company on remand: retatrutide is a drug, not a biological product (filed as Seventh Circuit No. 26-1301, Doc. 46-2)
FDA letter dated October 2, 2026, filed October 8, 2026 (2026)
regulatory fda biologic nda bla -
U.S. Food and Drug Administration
FDA Adverse Event Monitoring System (AEMS) Public Dashboard [formerly FAERS]: what the data can and cannot show
FDA web page (2026)
safety pharmacovigilance -
Giblin K, Kaplan LM, Somers VK, et al.
Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials
Diabetes, Obesity and Metabolism . 28 : 83-93 (2026)
phase-3 triumph trial-design dose-escalation obesity -
Grunstein RR, Somers VK, Azarbarzin A, et al.
Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea
New England Journal of Medicine (published online October 20, 2026) (2026)
phase-3 sleep-apnea osa triumph-1 triumph-2 -
Heerspink HJL, van Raalte DH, Bjornstad P, et al.
Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease
Nephrology Dialysis Transplantation . 41 : 1058-1068 (2026)
phase-2 ckd chronic-kidney-disease trial-design -
Jastreboff AM, Kaplan LM, Davies MJ, et al.
Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity
New England Journal of Medicine (published online September 29, 2026) (2026)
phase-3 triumph-1 obesity osteoarthritis sleep-apnea -
Eli Lilly and Company
Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications
Eli Lilly Press Release (June 6, 2026) (2026)
phase-3 triumph-1 transcend-t2d-1 press-release ADA-2026 -
Eli Lilly and Company
Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market
Eli Lilly Press Release (August 12, 2026) (2026)
gray-market enforcement lawsuit press-release -
Eli Lilly and Company
Lilly to present new data on Foundayo, retatrutide and eloraTZP at EASD 2026
Eli Lilly Press Release (September 15, 2026) (2026)
EASD conference triumph-2 press-release -
Eli Lilly and Company
FDA approves Lilly's Foundayo (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions
Eli Lilly Press Release (April 1, 2026) (2026)
orforglipron regulatory pricing press-release -
Eli Lilly and Company
Lilly reports second-quarter 2026 financial results, raises full-year guidance and highlights continued growth and pipeline progress
Eli Lilly Press Release (August 5, 2026) (2026)
regulatory BLA earnings press-release -
Eli Lilly and Company
Retatrutide head-to-head with Ozempic in TRANSCEND-T2D-2: topline results in adults with type 2 diabetes
Eli Lilly Press Release (October 28, 2026) (2026)
phase-3 transcend-t2d-2 press-release type-2-diabetes semaglutide -
Eli Lilly and Company
Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial
Eli Lilly Press Release (2026)
phase-3 triumph-1 press-release obesity weight-loss -
Eli Lilly and Company
Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
Eli Lilly Press Release (July 23, 2026) (2026)
phase-3 triumph-2 triumph-3 press-release type-2-diabetes cardiovascular BLA -
Lilly Medical
What dosages of Foundayo (orforglipron) capsules are equivalent to the tablet dosages?
Lilly Medical Information (US) (2026)
orforglipron dosing -
Novo Nordisk A/S
Financial report for the period 1 January 2026 to 30 June 2026 (company announcement No 48/2026, August 4, 2026)
Form 6-K, U.S. Securities and Exchange Commission (2026)
semaglutide cagrisema amycretin pricing medicare -
Novo Nordisk A/S
CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity; the primary endpoint was not achieved (February 23, 2026)
Novo Nordisk Company Announcement (2026)
cagrisema tirzepatide phase-3 -
Rosenstock J, Frias JP, Hartman ML, et al.
Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes (TRANSCEND-T2D-1): a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet (2026)
phase-3 type-2-diabetes hba1c TRANSCEND-T2D-1 clinical-trial peer-reviewed -
Rubin R
Unapproved GLP-1 Drugs Retatrutide and Zenagamtide Sold Online Are No Bargain
JAMA (published online October 9, 2026) (2026)
gray-market news -
Sehgal NKR, Tronieri JS, Rader B, et al.
Self-Reported Adverse Effects Among Social Media Users Taking Nonapproved Retatrutide
JAMA Network Open . 9(10) : e2638929 (2026)
real-world gray-market side-effects social-media -
STAT News
Lilly gave one patient early access to retatrutide. Now other doctors want the same for their patients
STAT News (August 3, 2026) (2026)
expanded-access news -
SYNCHRONIZE-2 investigators
Survodutide in adults with obesity or overweight and type 2 diabetes (SYNCHRONIZE-2), published October 1, 2026
New England Journal of Medicine (2026)
survodutide phase-3 -
Therapeutic Goods Administration (Australia), ABC News
TGA tests counterfeit 'retatrutide' after serious adverse event: product contained no retatrutide but roughly eight times the semaglutide of approved products
TGA Safety Alert / ABC News (September 14, 2026) (2026)
counterfeit gray-market safety TGA
2025
-
Coskun T, Wu Q, Schloot NC, et al.
Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial
Lancet Diabetes & Endocrinology . 13 : 674-684 (2025)
phase-2 body-composition DEXA fat-mass lean-mass type-2-diabetes -
U.S. Food and Drug Administration
FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (semaglutide shortage resolved February 21, 2025; tirzepatide shortage resolved December 19, 2024)
FDA Drug Alerts and Statements (2025)
compounding semaglutide tirzepatide regulatory -
Novo Nordisk
SAXENDA (liraglutide) injection 3 mg. Prescribing Information
U.S. Food and Drug Administration, Drugs@FDA (2025)
liraglutide label safety -
Garvey WT, et al.
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1)
New England Journal of Medicine (2025)
cagrisema phase-3 -
Jastreboff AM, et al.
Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity: A Phase 2 Trial
New England Journal of Medicine . 393 : 843-857 (2025)
maritide phase-2 -
Heerspink HJL, Lu Z, Du Y, et al.
The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity
Kidney International Reports . 10 : 1980-1992 (2025)
phase-2 kidney renal albuminuria egfr -
Eli Lilly and Company
Lilly's retatrutide (LY3437943) showed statistically significant and clinically meaningful results in TRIUMPH-4 Phase 3 trial
Eli Lilly Press Release (2025)
phase-3 triumph-4 press-release obesity osteoarthritis -
National Heart, Lung, and Blood Institute
Sleep Apnea
NHLBI Health Topics (updated January 9, 2025) (2025)
sleep-apnea -
Novo Nordisk A/S
Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity (company announcement No 4/2025, January 24, 2025)
Novo Nordisk Company Announcement (2025)
amycretin phase-2 -
U.S. District Court for the Southern District of Indiana
Eli Lilly and Company v. Kennedy, No. 1:24-cv-01503-TWP-KMB, amended order on cross-motions for summary judgment (October 3, 2025) and final judgment (December 16, 2025)
Federal court record (2025)
regulatory litigation -
Wharton S, et al.
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1)
New England Journal of Medicine . 393 : 1796-1806 (2025)
orforglipron phase-3
2024
-
Eli Lilly and Company
Lilly provides update on retatrutide phase 3 clinical development program for obesity and type 2 diabetes
Eli Lilly Press Release (2024)
regulatory phase-3 development press-release -
U.S. Food and Drug Administration
FDA Approves First Medication for Obstructive Sleep Apnea (December 20, 2024)
FDA News Release (2024)
tirzepatide sleep-apnea regulatory -
Frias JP, Hsia S, Engberg S, et al.
Retatrutide cardiovascular safety and metabolic parameters in the Phase 2 obesity trial
Diabetes, Obesity and Metabolism (2024)
cardiovascular safety phase-2 metabolic -
Malhotra A, Grunstein RR, Fietze I, et al.
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
New England Journal of Medicine . 391 : 1193-1205 (2024)
tirzepatide sleep-apnea osa surmount-osa -
Ryan DH, Yockey SR, Garvey WT
GLP-1 receptor agonists and obstructive sleep apnea
Obesity Reviews (2024)
sleep-apnea osa glp-1 -
Sanyal AJ, Kaplan LM, Frias JP, et al.
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
Nature Medicine . 30 : 2037-2048 (2024)
masld mash liver-fat phase-2 mri-pdff -
Wilding JPH, Batterham RL, Davies M, et al.
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
Diabetes, Obesity and Metabolism (2024)
semaglutide weight-regain step-trial
2023
-
European Medicines Agency
Mounjaro (tirzepatide): EPAR (EU authorisation September 15, 2022; CHMP positive opinion on weight management extension, November 2023)
European Medicines Agency (2023)
tirzepatide regulatory eu -
Eli Lilly and Company
ZEPBOUND (tirzepatide) injection. Prescribing Information (initial US approval 2023)
U.S. Food and Drug Administration, Drugs@FDA (2023)
tirzepatide label safety -
Jastreboff AM, Kaplan LM, Frias JP, et al.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
New England Journal of Medicine . 389 : 514-526 (2023)
phase-2 obesity weight-loss clinical-trial -
Medicines and Healthcare products Regulatory Agency
MHRA authorises diabetes drug Mounjaro (tirzepatide) for weight management and weight loss (November 8, 2023)
GOV.UK Press Release (2023)
tirzepatide regulatory uk -
Rosenstock J, Frias J, Jastreboff AM, et al.
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
The Lancet . 402 : 529-544 (2023)
phase-2 type-2-diabetes glycemic-control clinical-trial -
Rosenstock J, Frias J, Jastreboff AM, et al.
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
The Lancet . 402 : 529-544 (2023)
phase-2 type-2-diabetes hba1c clinical-trial -
Thomas MK, Nikooienejad A, Bray R, et al.
Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes
Diabetes Care (2023)
tirzepatide mechanism beta-cell
2022
-
Briere DA, Bueno AB, Gunn EJ, et al.
Mechanisms to elevate endogenous GLP-1 beyond injectable GLP-1 analogs and metabolic surgery
Molecular Metabolism (2022)
glp-1 mechanism review -
Coskun T, Urva S, Roell WC, et al.
LY3437943, a novel triple GIP/GLP-1/glucagon receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept
Cell Metabolism . 34 : 1234-1247.e9 (2022)
preclinical pharmacology mechanism phase-1 -
Coskun T, Urva S, Roell WC, et al.
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept
Cell Metabolism . 34 : 1234-1247.e9 (2022)
preclinical pharmacology mechanism discovery -
Eli Lilly and Company
MOUNJARO (tirzepatide) injection. Prescribing Information (initial US approval 2022)
U.S. Food and Drug Administration, Drugs@FDA (2022)
tirzepatide label safety -
U.S. Food and Drug Administration
PDUFA Reauthorization Performance Goals and Procedures, Fiscal Years 2023 Through 2027
FDA commitment letter (2022)
regulatory pdufa -
Urva S, Coskun T, Loh MT, et al.
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
The Lancet . 400 : 1869-1881 (2022)
phase-1 type-2-diabetes dose-finding pharmacokinetics
2021
-
Novo Nordisk
WEGOVY (semaglutide) injection 2.4 mg. Prescribing Information (initial US approval 2021)
U.S. Food and Drug Administration, Drugs@FDA (2021)
semaglutide label safety
2020
-
U.S. Code of Federal Regulations
21 CFR 600.3(h)(6): definition of protein (an alpha amino acid polymer with a specific, defined sequence greater than 40 amino acids in size)
Electronic Code of Federal Regulations (2020)
regulatory biologic -
U.S. Food and Drug Administration
Notice to Compounders: Changes That Affect Compounding on March 23, 2020
FDA compounding page (2020)
regulatory compounding -
U.S. Food and Drug Administration
The "Deemed to be a License" Provision of the BPCI Act
FDA guidance page (2020)
regulatory biologic
2017
-
Novo Nordisk
OZEMPIC (semaglutide) injection. Prescribing Information (initial US approval 2017)
U.S. Food and Drug Administration, Drugs@FDA (2017)
semaglutide label safety